Physician profile
Lori D Stetler
NPI 1235137357
$17,719.44
in general payments reported to CMS, 2019-2025
32 companies · $762 in 2025
The $762 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,320 · 2020: $3,418 · 2021: $8,128 · 2022: $616 · 2023: $543 · 2024: $932 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13,446.59 | 2019-2022 | |
| Abbvie INC. | $1,753.12 | 2019-2025 | Botox, Skyrizi |
| Galderma Laboratories, L.P. | $519.36 | 2019-2025 | Dysport |
| Solta Medical, A Division of Bausch Health US, LLC | $296.16 | 2020-2025 | Fraxel |
| Sun Pharmaceutical Industries INC. | $238.51 | 2019-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $146.43 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $137.12 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $115.63 | 2020-2024 | |
| Epi Health, LLC | $113.90 | 2019-2021 | |
| Leo Pharma INC. | $103.33 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $81.92 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Prugen, INC. Pharmaceuticals | $71.32 | 2019 | |
| Vyne Pharmaceuticals INC. | $69.43 | 2020-2021 | |
| Genzyme Corporation | $65.32 | 2022-2025 | |
| Aclaris Therapeutics, INC. | $52.88 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $52.58 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $44.25 | 2024-2025 | Zoryve |
| Almirall LLC | $41.52 | 2019-2021 | |
| Lilly USA, LLC | $39.90 | 2021 | |
| Incyte Corporation | $37.40 | 2022-2024 | Opzelura |
| Dermavant Sciences, INC. | $35.88 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $34.84 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $31.92 | 2025 | Ycanth |
| Merz North America, INC. | $31.11 | 2020-2024 | |
| Botanix Sb INC | $23.62 | 2025 | Sofdra |
| Glenmark Therapeutics INC. | $23.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $21.96 | 2021 | |
| Scynexis, INC. | $20.58 | 2022 | |
| Celgene Corporation | $19.68 | 2019 | |
| Janssen Biotech, INC. | $18.89 | 2021 | |
| Revance Therapeutics, INC. | $16.73 | 2025 | Daxxify |
| Medtronic, INC. | $14.56 | 2025 | Midas Rex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Stetler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.